EyePoint Pharmaceuticals, Inc.

As of August 26, 2025, EyePoint Pharmaceuticals, Inc. shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite a bearish monthly KST, and has significantly outperformed the S&P 500 with a year-to-date return of 84.70%.

As of May 27, 2025, EyePoint Pharmaceuticals, Inc. shows a mildly bearish trend due to conflicting signals from moving averages and Bollinger Bands, despite a recent strong monthly performance contrasting with a significant weekly decline.

As of March 2022, the management team of EyePoint Pharmaceuticals, Inc. includes Dr. Goran Ando (Independent Chairman), Nancy Lurker (CEO), and several directors: Wendy DiCicco, Ye Liu, Ronald Eastman, Douglas Godshall, and David Guyer. They oversee the company's strategic direction and operations.

EyePoint Pharmaceuticals, Inc. develops drug delivery products for chronic eye diseases and has a market cap of $606.23 million. As of March 2025, it reported net sales of $24 million and a net loss of $45 million.

As of Jun 18, EyePoint Pharmaceuticals, Inc. has a market capitalization of 606.23 million, with net sales of 56.04 million and a net profit of -146.79 million over the last four quarters. The company's balance sheet shows shareholder's funds of 336.50 million and total assets of 418.46 million.